Concepedia

Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa

M Kolou, Armel Poda, Zélica Diallo, Esther Konou, Tatiana Dokpomiwa, Jacques Zoungrana, Mounérou Salou, Lionèle Mba-Tchounga, André Bigot, Abdoul–Salam Ouédraogo,

BMC Immunology · 2021 · 15 citations · 26 references

DOIFull text

Open access

Abstract

HLA-B*57:01 prevalence is low in individuals with HIV in West and central Africa, and there is no difference among countries. This study does not confirm the utility of HLA-B*57:01 allele testing for abacavir use in this region.

References

26

HLA-B*5701 Screening for Hypersensitivity to Abacavir

S. Mallal, Elizabeth J. Phillips, Giampiero Carosi et al. · New England Journal of Medicine · 2008 · 1.8K citations · Full text

Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations

Kai Cao, Jill A. Hollenbach, Xuejiang Shi et al. · Human Immunology · 2001 · 465 citations

, , +15

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

Seth Hetherington, Sue McGuirk, Gwendolyn Powell et al. · Clinical Therapeutics · 2001 · 413 citations

, , +8

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing

Susan G. Leckband, John R. Kelsoe, Henry M. Dunnenberger et al. · Clinical Pharmacology & Therapeutics · 2013 · 328 citations · Full text

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

Dyfrig Hughes, F. Javier Vilar, Charlotte C Ward et al. · Pharmacogenetics · 2004 · 289 citations